The India cell and gene therapy market size reached USD 710.91 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,513.14 Million by 2033, exhibiting a growth rate (CAGR) of 15.10% during 2025-2033. Rising prevalence of genetic disorders, growing investments in biotechnology, regulatory support for advanced therapies, increasing clinical trials, demand for personalized medicine, expanding healthcare infrastructure, technological advancements in gene editing, availability of skilled researchers, collaborations between academia and industry, and a surge in stem cell research are key drivers shaping market growth.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024 |
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 710.91 Million |
Market Forecast in 2033 | USD 2,513.14 Million |
Market Growth Rate (2025-2033) | 15.10% |
Expansion of Domestic Manufacturing and Infrastructure
India is witnessing significant investment in domestic cell and gene therapy manufacturing to reduce dependency on imports. Leading biotechnology firms and pharmaceutical companies are establishing Good Manufacturing Practice (GMP)-compliant facilities to produce vector-based and autologous therapies. Government initiatives are further encouraging indigenous production. This expansion is expected to improve affordability, streamline regulatory approvals, and accelerate market access for innovative therapies. Additionally, contract development and manufacturing organizations (CDMOs) are gaining traction as key players in supporting large-scale production. The establishment of dedicated cell therapy centers and regulatory-backed infrastructure projects positions India as a competitive hub for cell and gene therapy innovation in the Asia-Pacific region. For instance, in April 2024, the Government of India (GoI) launched country’s first homegrown gene therapy for cancer, CAR-T cell therapy, at IIT Bombay. Developed in collaboration with Tata Memorial Hospital and ImmunoACT, it is the world’s most affordable CAR-T therapy. The initiative aligns with ‘Make in India’ and ‘Atmanirbhar Bharat,’ making advanced cancer treatment accessible. The therapy, a major medical breakthrough, leverages academia-industry partnerships, reinforcing India’s role in cutting-edge healthcare innovation and technological self-reliance.
Increasing Clinical Trials and Regulatory Advancements
India is emerging as a strategic location for clinical trials in cell and gene therapy, driven by a large patient pool and cost-effective research capabilities. The Central Drugs Standard Control Organization (CDSCO) is implementing structured regulatory pathways, streamlining approval processes for experimental therapies. The introduction of accelerated approvals for orphan diseases and rare genetic disorders is further fueling trial activity. Additionally, collaborations between Indian research institutions and global biotech firms are facilitating multicenter trials, leading to faster clinical validation of therapies. As regulatory frameworks evolve to align with international standards, India’s attractiveness as a research and development hub for advanced therapeutic medicinal products (ATMPs) is increasing, creating an ecosystem conducive to innovation and commercialization. For instance, in February 2024, India approved its first homegrown CAR T-cell therapy, NexCAR19. Developed by ImmunoACT, a spin-off of IIT Bombay, it was tested in 64 patients with lymphoma or leukemia, achieving a 67% response rate. The therapy, licensed for manufacturing in Mumbai, aims to treat 1,200 patients annually. Collaboration with NCI scientists helped refine its development, ensuring accessibility in India’s healthcare system.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the region/country level for 2025-2033. Our report has categorized the market based on therapy type, indication, delivery mode, and end user.
Therapy Type Insights:
The report has provided a detailed breakup and analysis of the market based on the therapy type. This includes cell therapy (stem cell (pluripotent stem cell, cancer stem cell, and adult stem cell) and non-stem cell (t-cell, natural killer cell, and others)) and gene therapy.
Indication Insights:
A detailed breakup and analysis of the market based on the indication have also been provided in the report. This includes cardiovascular disease, oncology disorder, genetic disorder, infectious disease, neurological disorder, and others.
Delivery Mode Insights:
A detailed breakup and analysis of the market based on the delivery mode have also been provided in the report. This includes in-vivo and ex-vivo.
End User Insights:
A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals, cancer care centers, pharmaceuticals and biotechnology companies, and others.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include North, South, East, and West India.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Therapy Types Covered |
|
Indications Covered | Cardiovascular Disease, Oncology Disorder, Genetic Disorder, Infectious Disease, Neurological Disorder, Others |
Delivery Modes Covered | In-Vivo, Ex-Vivo |
End Users Covered | Hospitals, Cancer Care Centers, Pharmaceuticals And Biotechnology Companies, Others |
Regions Covered | North India, South India, East India, West India |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
Key Benefits for Stakeholders: